MEMSCAP (NYSE Euronext:
MEMS), the leading provider of innovative solutions based on MEMS (micro-electro-mechanical
systems) technology and CARMAT, a Company specialized in the elaboration of
biomaterials and advanced technologies applied to the field of artificial heart,
today announce a partnership in the frame of development and industrialization
of the first fully implantable artificial heart.
For MEMSCAP, this partnership confirms its major presence in the biomedical
revolutionary products enhancing human lives. For CARMAT, this partnership,
which benefits from
MEMSCAP' experience and technologies, allows to realize spectacular progress
in the development and
industrialization of implantable artificial heart, thus contributing to save
thousands of human lives.
The CARMAT patented artificial heart prototype respects the biocompatibility
criteria enabling its
implantation in the human body. Its features are similar to a biological heart,
both on the physiological
and the anatomy levels.
The system, composed from an implantable part, a portable part as well as
external devices supplying
power and assuring its control and monitoring, integrates MEMSCAP sensors to
cardiac output and frequency in function of the patient physiological needs,
such as physical effort.
"CARMAT has chosen to dedicate its activity to a major scientific challenge
and to open new medical
approaches. We are proud to help them realize those challenges and to offer
an advanced system aiming
to save multiple human lives », said Jan Hallenstvedt, General Manager
of MEMSCAP' Standard
Products Business Unit.
"MEMSCAP has been selected as we needed a partner having a strong experience
capable of supplying us high quality products with extreme precision and very
low time drift, showing
strong robustness for many years », explained Marc Grimmé, Technical
Director of CARMAT.